



Innovative back microsurgery

Press release

A retrospective study of 178 patients followed over 5 years confirms the excellent long term results of SpineJack® for treating vertebral compression fractures

The study found that the reduction-stabilisation of vertebral fractures through a combination of SpineJack® implantation and cement injection resulted in immediate and sustained improvement of the patient's pain and functional capabilities.

Toulouse, March 10, 2014 - VEXIM (FR0011072602 - ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, announces today that the results of a long term retrospective study of 178 patients confirm the effectiveness of SpineJack® for treating vertebral compression fractures.

This single-center, retrospective, observational, consecutive study was conducted by Prof. David Noriega, orthopedic surgeon at the Hospital Clinico Universitario in Valladolid, Spain.

The study included 178 patients suffering from vertebral fractures due to trauma, osteoporosis or cancer tumors who were studied over the course of five years after SpineJack®¹ implantation.

The intention of this retrospective analysis was to evaluate the morbidity, effect on pain and improvement of patient's autonomy, as well as the sustainability of the correction achieved over time and the consequences of this restoration on development of adjacent vertebral fractures.

Vertebral pain was assessed using a Visual Analog Scale (VAS) and showed a statistically significant decrease of 75% at the end of the observation period.

Functional capacity was measured using the Oswestry Disability Index (ODI). Results showed a significant improvement of 92% at the end of the evaluation period.

In this study with an observation period of up to five years, and with almost 60% of osteoporotic fractures or fractures associated with osteoporosis, a very low rate of adjacent vertebral fractures (2.2%) was observed. These excellent results suggest a dramatic reduction in morbidity in vertebral fractures treated with the SpineJack®. The rate of adjacent fractures published in literature^{2,3} on vertebroplasty and kyphoplasty is between 11% and 21%. It also confirms the excellent results from

¹ 1st and 2nd generation of the SpineJack®

² Lindsay R, Silverman SL, Cooper C et al. (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320-323.

³ Fribourg D, Tang C, Sra P, Delamarter R, Bae H. Incidence of subsequent vertebral fracture after kyphoplasty. Spine. 2004;29:2270-6

the previously disclosed international clinical study of 103 patients with vertebral fractures due to trauma, and the results of the first retrospective study on 77 patients performed last year in France.

Prof. David Noriega comments: *“We believe that this very low rate of adjacent compression fracture is directly associated with the quality of fracture reduction and restoration of sagittal balance. As a result, it positively affects the quality and maintenance of our very good long term clinical outcomes especially when it comes to re-establishing independence and quality of life for every type of patients”*.

2014 preliminary financial agenda*:

FY 2013 results: March 18, 2014

Q1 2014 sales: April 15, 2014

H1 2014 sales: July 22, 2014

*Indicative dates, subject to potential modifications

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital⁴ and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack[®], a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3rd 2012.

For further information, please go to www.vexim.com

SpineJack^{®5}, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack[®] lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack[®] range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack[®] technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

⁴ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

⁵ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Contacts

VEXIM

Vincent Gardès

CEO

Jérôme Marzinski

Deputy CEO

Tel: +33 5 61 48 48 38

shareholders@vexim.com

NewCap.

Financial Communications
and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol

caroline@alizerp.com

Tel: +33 1 70 22 53 90 /

+33 6 64 18 99 59



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM